Abbott's troponin test for Architect systems:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories has received US FDA 510(k) clearance to run a test for the cardiac marker troponin I on its Architect line of immunoassay and immunochemistry analysers, the i2000SR and ci8200, respectively. The test marks the second assay in Abbott's acute cardiac panel for the Architect platform, says the Abbott Park, Illinois firm, which is developing additional cardiac assays. It is already available in major markets outside the US. The company added that based on the American College of Cardiology's new criteria for diagnosing heart attack, troponin has become the gold standard in diagnostic testing.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.